Malaria, Plasmodium Vivax
Conditions
Keywords
Malaria, Plasmodium Vivax, Vaccine
Brief summary
This is a first-in-humans safety, immunogenicity and efficacy study with recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine. This open label study will be performed in malaria-naïve adults in the United States. Three doses of VMP001 formulated in AS01B (adjuvant system) will be given intramuscularly at different intervals followed by a challenge with P. vivax infected mosquitoes. Safety, immunogenicity and efficacy parameters will be studied.
Detailed description
This is a Phase 1/2a, non-randomized, open label, dose escalation study in healthy, malaria-naïve adults aged 18 to 55 years (inclusive). The vaccine will be administered with GlaxoSmithKline Biologicals' adjuvant system AS01B. This is a first-in-human study of VMP001; therefore the study design will incorporate a dose-escalation phase evaluating 15 µg, 30 µg, and 60 µg doses of VMP001 in 500 µL of AS01B. A total of 30 volunteers, divided into 3 groups (10 in each group), will receive 3 doses of the VMP001/AS01B vaccine. Group 1 will receive 15 µg of VMP001, Group 2 will receive 30 µg of VMP001, and Group 3 will receive 60 µg of VMP001 at each immunization. The dose of AS01B will be 500 µL for all groups. The first and second dose in each group will be separated by 28 days. The third dose in the three groups will be given at intervals scheduled to normalize the time to challenge between the last immunization and challenge. The second and third dose in Group 1 will be separated by 56 days, Group 2 by 42 days and Group 3 by 28 days. The challenge will occur 2 weeks following the third immunization. A group of 6-12 infectivity controls will begin participation in the study at the challenge stage. They will not receive any immunizations or placebos prior to challenge. All volunteers will receive a standard treatment regimen consisting of chloroquine and primaquine on the day that parasitemia is detected. Volunteers who do not become parasitemic will also begin the same treatment regimen on day 28 following the challenge (study day 126). \> \> Safety and immunogenicity will be evaluated during the study through the final study visit 6 months after challenge (study day 280).
Interventions
BIOLOGICALVMP001
Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
OTHERP. vivax sporozoite challenge
P. vivax sporozoite challenge
Sponsors
The PATH Malaria Vaccine Initiative (MVI)
Walter Reed Army Institute of Research (WRAIR)
United States Department of Defense
GlaxoSmithKline
U.S. Army Medical Research and Development Command
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who meet all of the following criteria may participate in this study: * Healthy adults (male or non-pregnant, non-lactating female) 18 to 55 years of age (inclusive) at the time of enrollment * If the subject is female, she must be of non-childbearing potential (either surgically sterilized or one year post-menopausal) or, if of childbearing potential, she must be capable of preventing pregnancy, have a negative pregnancy test at the time of each vaccination, and must agree to continue such precautions until completion of the last study visit. * Free of significant health problems as established by medical history, laboratory and clinical examination before entering the study * Duffy positive phenotype (homozygous or heterozygous) * Normal (non-deficient) Glucose 6-phosphate dehydrogenase (G6PD) phenotype (range: 4.6 to 13.5 units/gm hemoglobin) * Volunteers must have low cardiac risk factors according to the NHANES I criteria and a non-significant electrocardiogram (EKG) * Available to participate and reachable by phone for duration of study (approximately 9 months) * No plans to travel to outside the Washington, District of Columbia (DC) area up until treatment course has been completed (post challenge) * No plans to travel to a malaria endemic area during the course of the study * Written informed consent must be obtained from the subject before screening procedures * Volunteers must score at least 80% correct on a 10 or 14 question multiple-choice quiz (control and immunization groups, respectively) that assesses their understanding of this study * If a subject is active duty military he or she must obtain approval from his or her supervisor per Walter Reed Army Institute of Research (WRAIR) Policy 06-15
Exclusion criteria
* Subjects meeting any of the following criteria will be excluded from the study: * Any history of malaria infection * History of travel to P. vivax endemic areas in the last three months, and travel to Republic of Korea or China in the last 18 months * Any history of receiving malaria vaccine or any licensed vaccine within 7 days prior to first immunization * History of receipt of malaria prophylaxis during the previous 2 months or the use of any drugs with significant anti-malarial activity during the study period one month prior to challenge (for control volunteers). Examples include tetracycline, doxycycline, clindamycin, azithromycin or sulfa drugs * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine or planned use during the study period. * Any history of allergic reaction or anaphylaxis to previous vaccination Allergy to kanamycin, nickel, or imidazole * Pregnant (positive β-HCG) or nursing at screening or plans to become pregnant or nurse from the time of enrollment until study completion. * Allergy to antimalarial drugs or use of medications known to cause drug reactions with chloroquine and/or primaquine * Significant (e.g. systemic) hypersensitivity reactions to mosquito bites (local hypersensitivity reactions at the site of mosquito bites are not an exclusion criterion) * History of sickle cell disease * History of psoriasis or porphyria * History of splenectomy * Any confirmed or suspected immunodeficiency, including HIV infection * Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune-modifying drugs within 6 months of immunization. For corticosteroids, this is defined as \>20 mg/day prednisone or equivalent. -Inhaled and topical steroids are allowed * A family history of congenital or hereditary immunodeficiency * Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by history, physical examination, and laboratory evaluation * History of diabetes or hypertension even if well controlled on medication * An abnormal baseline screening electrocardiogram (EKG) suggestive of cardiac disease as determined by a clinical investigator * Chronic or active neurologic disease including seizure disorder and chronic migraine headaches * Any abnormal baseline laboratory screening tests: Alanine Aminotransferase (ALT) above normal range, -Creatinine above normal range, Hemoglobin out of normal range, Platelet count out of normal range, Total white blood cell count out of normal range * Hepatomegaly, right upper quadrant abdominal pain or tenderness * Seropositive for HIV or hepatitis C virus, or HBsAg positive * Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or any planned administration during the study period * Suspected or known current alcohol or drug abuse as determined from the medical history or by physical examination * Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | 7 days after immunization | Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. |
| Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | 28 days following immunization | Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase |
| Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | up to 463 days | Occurrence of serious adverse events at any time during the approximately 463 day study period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Parasitemia for Immunogenicity Population | 280 day (during the study through 6 months aftr challenge) | Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear. Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy. |
| Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | study duration | Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '\>50' were converted to '1'. |
| Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | study duration | Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '\>50' were converted to '1'. |
Countries
United States
Participant flow
Recruitment details
41 patients were enrolled (30 vaccination group, 6 infectivity control group and 5 alternates) and received treatment at the Clinical Trials Center (CTC) at Walter Reed Army Institute of Research (WRAIR)
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: 15 μg VMP001 15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
VMP001: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
P. vivax sporozoite challenge: P. vivax sporozoite challenge | 10 |
| Cohort 2: 30 μg VMP001 30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
VMP001: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
P. vivax sporozoite challenge: P. vivax sporozoite challenge | 10 |
| Cohort 3: 60 μg VMP001 60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
VMP001: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
P. vivax sporozoite challenge: P. vivax sporozoite challenge | 10 |
| Control No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
P. vivax sporozoite challenge: P. vivax sporozoite challenge | 6 |
| Total | 36 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 0 | 0 | 1 |
| Overall Study | Relocated | 0 | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | Cohort 1: 15 μg VMP001 | Total | Control | Cohort 3: 60 μg VMP001 | Cohort 2: 30 μg VMP001 |
|---|---|---|---|---|---|
| Age, Continuous | 32.1 years STANDARD_DEVIATION 8.3 | 30.1 years STANDARD_DEVIATION 8 | 25.0 years STANDARD_DEVIATION 7.2 | 28.7 years STANDARD_DEVIATION 8 | 29.4 years STANDARD_DEVIATION 8.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants | 36 Participants | 6 Participants | 10 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 4 Participants | 0 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 28 Participants | 4 Participants | 8 Participants | 9 Participants |
| Region of Enrollment United States | 10 participants | 36 participants | 6 participants | 10 participants | 10 participants |
| Sex: Female, Male Female | 4 Participants | 13 Participants | 3 Participants | 4 Participants | 2 Participants |
| Sex: Female, Male Male | 6 Participants | 23 Participants | 3 Participants | 6 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 9 | 0 / 8 | 0 / 10 | 0 / 6 |
| other Total, other adverse events | 9 / 9 | 8 / 8 | 10 / 10 | 6 / 6 |
| serious Total, serious adverse events | 1 / 9 | 0 / 8 | 0 / 10 | 1 / 6 |
Outcome results
Primary
Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit)
Occurrence of serious adverse events at any time during the approximately 463 day study period
Time frame: up to 463 days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Not Related to study drug - Breast cancer (left) | 1 Participants |
| Cohort 1: 15 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Patients without SAE | 9 Participants |
| Cohort 1: 15 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Related to study drug | 0 Participants |
| Cohort 2: 30 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Not Related to study drug - Breast cancer (left) | 0 Participants |
| Cohort 2: 30 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Patients without SAE | 10 Participants |
| Cohort 2: 30 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Related to study drug | 0 Participants |
| Cohort 3: 60 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Related to study drug | 0 Participants |
| Cohort 3: 60 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Not Related to study drug - Breast cancer (left) | 0 Participants |
| Cohort 3: 60 μg VMP001 | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Patients without SAE | 10 Participants |
| Control | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Not Related to study drug - Breast cancer (left) | 0 Participants |
| Control | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Patients without SAE | 6 Participants |
| Control | Occurrence of Serious Adverse Events at Any Time During the Study Period (Enrollment to Final Follow up Visit) | Related to study drug | 0 Participants |
Primary
Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase
Adverse events were evaluated for 7 days after each vaccination during the vaccine phase.
Time frame: 7 days after immunization
Population: Control group was not included in the evaluation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Vomiting | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Myalgia | 4 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site pain | 10 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Diarrhea | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Nausea | 5 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Fatigue | 8 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Pyrexia | 4 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Arthralgia | 4 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Headache | 8 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site erythema | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site induration | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site pain | 10 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Diarrhea | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site erythema | 3 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Nausea | 3 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Headache | 6 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Fatigue | 4 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Pyrexia | 2 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Vomiting | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Arthralgia | 2 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Myalgia | 4 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site induration | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site erythema | 6 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Myalgia | 7 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site pain | 10 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Diarrhea | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Vomiting | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Local: Injection site induration | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Nausea | 4 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Arthralgia | 3 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Pyrexia | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Fatigue | 7 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase | Solicited Systemic: Headache | 5 participants with AEs |
Primary
Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase
Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase
Time frame: 28 days following immunization
Population: Control group was not included in this evaluation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Haemoglobin decreased | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site erythema | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Ear discomfort | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Skin laceration | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site pruritus | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Headache | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Scratch | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site swelling | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dizziness | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Posttraumatic pain | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site warmth | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal discomfort | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Postprocedural discomfort | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Malaise | 3 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Seasonal allergy | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Excoriation | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertransaminasaemia | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Pain in extremity | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Contusion | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasopharyngitis | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feces discolored | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Upper respiratory tract infection | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Erythema | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Myalgia | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Food poisoning | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal pain | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Musculoskeletal discomfort | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nausea | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dermatitis contact | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Muscle spasms | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Toothache | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasal Congestion | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Back pain | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Axillary pain | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Sinus headache | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Gout | 1 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Chills | 5 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Cold sweat | 2 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Platelet count decreased | 0 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feeling hot | 5 participants with AEs |
| Cohort 1: 15 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertension | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Posttraumatic pain | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal pain | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Seasonal allergy | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Headache | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Sinus headache | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Cold sweat | 4 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Ear discomfort | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal discomfort | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feces discolored | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Food poisoning | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nausea | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Toothache | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Axillary pain | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Chills | 5 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feeling hot | 6 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site erythema | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site pruritus | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site swelling | 2 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site warmth | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Malaise | 5 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertransaminasaemia | 2 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasopharyngitis | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Upper respiratory tract infection | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Contusion | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Excoriation | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Postprocedural discomfort | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Scratch | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Skin laceration | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Haemoglobin decreased | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Platelet count decreased | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Gout | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Back pain | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Muscle spasms | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Musculoskeletal discomfort | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Myalgia | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Pain in extremity | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dizziness | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasal Congestion | 0 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dermatitis contact | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Erythema | 1 participants with AEs |
| Cohort 2: 30 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertension | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertension | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Skin laceration | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feeling hot | 7 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dizziness | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Haemoglobin decreased | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Chills | 7 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasal Congestion | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Platelet count decreased | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Axillary pain | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Erythema | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Gout | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Toothache | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Cold sweat | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Back pain | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nausea | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Sinus headache | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Muscle spasms | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Food poisoning | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Seasonal allergy | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Musculoskeletal discomfort | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Feces discolored | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Dermatitis contact | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Nasopharyngitis | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Myalgia | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Upper respiratory tract infection | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Hypertransaminasaemia | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal pain | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Contusion | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Malaise | 7 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Headache | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Excoriation | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site warmth | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Pain in extremity | 2 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Postprocedural discomfort | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site swelling | 3 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Abdominal discomfort | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Posttraumatic pain | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site pruritus | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Ear discomfort | 0 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Scratch | 1 participants with AEs |
| Cohort 3: 60 μg VMP001 | Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase | Injection site erythema | 1 participants with AEs |
Secondary
Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '\>50' were converted to '1'.
Time frame: study duration
Population: Efficacy population
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post second vaccination | 20161.18 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Pre-vaccination | 1 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post first vaccination | 133.72 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of second vaccination | 244.35 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of third vaccination | 9053.32 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post third vaccination | 61203.48 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 4wks post challenge | 54843.38 Geometric Mean Titier of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 6mths post challenge | 10860.7 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 4wks post challenge | 56472.17 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post second vaccination | 81143.72 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of third vaccination | 31071.01 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post third vaccination | 68730.4 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Pre-vaccination | 1 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 6mths post challenge | 12519.16 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post first vaccination | 750.38 Geometric Mean Titier of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of second vaccination | 1450.22 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Pre-vaccination | 3.09 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of second vaccination | 1711.63 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post third vaccination | 41879.99 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post second vaccination | 61711.8 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 4wks post challenge | 32178.39 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 2wks post first vaccination | 836.68 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | Day of third vaccination | 36405.66 Geometric Mean Titier of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population | 6mths post challenge | 5500.73 Geometric Mean Titier of European Units |
Secondary
Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '\>50' were converted to '1'.
Time frame: study duration
Population: Immunogenicity population
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Pre-vaccination | 1 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post first vaccination | 151.39 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of second vaccination | 281.79 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post second vaccination | 21862.22 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of third vaccination | 9921.61 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post third vaccination | 59883.77 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 4wks post challenge | 54843.38 Geometric Mean Titer of European Units |
| Cohort 1: 15 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 6months post challenge | 10860.7 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of second vaccination | 1175.41 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 4wks post challenge | 56472.17 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post second vaccination | 74608.62 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of third vaccination | 28498.43 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post third vaccination | 68730.4 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Pre-vaccination | 1.5 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post first vaccination | 526.18 Geometric Mean Titer of European Units |
| Cohort 2: 30 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 6months post challenge | 12519.16 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of second vaccination | 1711.63 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post first vaccination | 836.68 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Pre-vaccination | 3.09 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post second vaccination | 61711.8 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 4wks post challenge | 32178.39 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 2wks post third vaccination | 41879.99 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | Day of third vaccination | 36405.66 Geometric Mean Titer of European Units |
| Cohort 3: 60 μg VMP001 | Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population | 6months post challenge | 5500.73 Geometric Mean Titer of European Units |
Secondary
Time to Parasitemia for Immunogenicity Population
Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear. Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy.
Time frame: 280 day (during the study through 6 months aftr challenge)
Population: Drop-outs prior to vaccination were not included in the analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: 15 μg VMP001 | Time to Parasitemia for Immunogenicity Population | 0.137 days | Standard Error 2.025 |
| Cohort 2: 30 μg VMP001 | Time to Parasitemia for Immunogenicity Population | 0.073 days | Standard Error 2.106 |
| Cohort 3: 60 μg VMP001 | Time to Parasitemia for Immunogenicity Population | 0.042 days | Standard Error 2.154 |